Clinical trials: Paragangliomas
Paraganglioma, Gastrointestinal Stromal Tumors
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Background: Wild-type gastrointestinal stromal tumor (GIST) is a cancer in the esophagus, stomach, or intestines. It does not respond well to standard chemotherapy or radiation therapy.
- Conditions
- Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms
- Trial name
- NCT03165721
- Testing
- SGI-110 (guadecitabine)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Spinal Metastases, Vertebral Metastases
Stereotactic Body Radiotherapy for Spine Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of spine metastases and benign spine tumors.
- Conditions
- Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma
- Trial name
- NCT01347307
- Testing
- SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mercy Research
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumor, Paraganglioma
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive…
- Conditions
- Neuroendocrine Tumor, Paraganglioma, Carcinoid Tumors, Neuroblastoma
- Trial name
- DOTA-TOC (NCT02177773)
- Testing
- Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Paraganglioma, Pheochromocytoma
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
This is an open-label phase II study of an investigational drug, sunitinib malate in patients with advanced malignant paraganglioma or phaeochromocytoma cancer.
- Trial name
- SNIPP (NCT00843037)
- Testing
- Sunitinib
- Where
- 4 sites in Canada, Netherlands
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced or progressive malignant pheochromocytoma or paraganglioma.
- Conditions
- Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Paraganglioma, Recurrent Adrenal Gland Pheochromocytoma
- Trial name
- NCT01340794
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 11 sites in United States, Hong Kong and 1 more
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor
Phase 2 Study of ONC201 in Neuroendocrine Tumors
The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in…
- Trial name
- NCT03034200
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter Anderson
Head and Neck Neoplasms, Pheochromocytoma
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Background: The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
- Conditions
- Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00923481
- Testing
- Fostamatinib disodium
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Pheochromocytoma, Paraganglioma
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Background: Most treatments for malignant pheochromocytomas/paragangliomas (PHEO/PGL) are palliative and multidisciplinary. Chemotherapy using the combination of cyclophosphamide, vincristine, and dacarbazine has been…
- Trial name
- NCT01967576
- Testing
- Axitinib (AG-013736)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Pheochromocytoma, Paraganglioma
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
This clinical trial is designed to evaluate the effectiveness and collect additional safety information on AZEDRA® (iobenguane I 131) for the treatment of metastatic or relapsed/refractory (to other treatment) or unresectable…
- Trial name
- NCT00874614
- Testing
- Ultratrace® Iobenguane I131
- Where
- 10 sites in United States
- Volunteers
- 74 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Pheochromocytoma, Paraganglioma
Preoperative Alpha Blockade for Pheochromocytoma
Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and…
- Trial name
- NCT03176693
- Testing
- Phenoxybenzamine, Doxazosin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, Los Angeles
Pheochromocytoma, Paraganglioma
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
This is an ongoing prospective Phase II clinical trial evaluating the efficacy of 131I-MIBG for the treatment of patients with metastatic or unresectable pheochromocytoma and related tumors.
- Trial name
- NCT01413503
- Testing
- 131I-MIBG
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Carney Complex, Chondrosarcoma
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors.
- Conditions
- Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
- Trial name
- NCT01560260
- Testing
- Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Vestibular Schwannoma
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma…
- Trial name
- NCT04351373
- Testing
- Fluorescein Sodium, YELLOW560 filter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Pheochromocytoma, Paraganglioma
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
- Trial name
- NCT00458952
- Testing
- Ultratrace Iobenguane (MIBG) I 131
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Neuroendocrine Tumors
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
- Trial name
- NCT00843531
- Testing
- RAD001, erlotinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
This phase II trial studies how well lenvatinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
- Trial name
- NCT03008369
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic